Citi Raises Arcturus Therapeutics Price Target to $49, Keeps Buy Rating

Citi raised the price target for Arcturus Therapeutics (ARCT) to $49 from $47 and maintained a Buy rating. The firm believes the upcoming ARCT-032 Phase 2 readout in September offers a favorable risk/reward.

Title: Citigroup Raises Price Target for Arcturus Therapeutics (ARCT)

Citigroup analyst Yigal Nochomovitz maintained a "Buy" rating for Arcturus Therapeutics (ARCT) and raised the price target for the stock to $49.00 from the previous target of $47.00. This adjustment reflects a 4.26% increase in the price target, announced on August 12, 2025 [1].

The recent upgrade comes as Arcturus Therapeutics reported better-than-expected Q2 financial results, driving a 27.9% increase in stock price to $14.56 [2]. The company's pipeline includes promising therapeutic candidates such as LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19, which are focused on rare diseases like cystic fibrosis and respiratory conditions.

Analysts are particularly optimistic about the upcoming ARCT-032 Phase 2 readout in September, which Citigroup believes offers a favorable risk/reward profile. The company is also advancing enrollment for adult CF participants in its Phase 2 multiple ascending dose CF study and expects to complete enrollment as planned by year-end [3].

Arcturus Therapeutics' financial results for the second quarter ended June 30, 2025, showed revenues of $28.3 million and $57.7 million for the three and six months, respectively, representing decreases compared to the same periods in 2024. Operating expenses were $39.9 million for the three months and $86.1 million for the six months, reflecting a decrease driven by lower manufacturing costs and reduced clinical trial expenses [3].

Based on the one-year price targets offered by 10 analysts, the average target price for Arcturus Therapeutics is $61.80, with a high estimate of $140.00 and a low estimate of $25.00. The average target implies an upside of 442.58% from the current price of $11.39 [1].

The consensus recommendation from 11 brokerage firms is currently 1.5, indicating a "Buy" status. GuruFocus estimates the GF Value for Arcturus Therapeutics in one year to be $15.84, suggesting an upside of 39.07% from the current price of $11.39 [1].

References:
[1] https://www.gurufocus.com/news/3055345/citigroup-raises-price-target-for-arcturus-therapeutics-arct-to-49-arct-stock-news
[2] https://www.inkl.com/news/mercury-systems-posts-better-than-expected-earnings-joins-green-dot-arcturus-therapeutics-and-other-big-stocks-moving-higher-on-tuesday
[3] https://finance.yahoo.com/news/arcturus-therapeutics-announces-second-quarter-200100265.html